House spending bill omits PRV reauthorization, slashes biomedical research program

With Congress facing a Friday deadline to pass legislation to avoid a government shutdown, lawmakers are considering a bill passed by the House that fails to revive a powerful incentive for pediatric drug development, slashes funding for innovative biomedical research, and gives HHS Secretary Robert F. Kennedy Jr. authority to rapidly implement his agenda without seeking Congressional consent.

In a break from tradition, the House bill does not include specific funding instructions for key programs, a move that shifts power from Congress to the Trump administration. ...